IceCure Medical (ICCM) Cash & Equivalents (2020 - 2026)

IceCure Medical (ICCM) has reported Cash & Equivalents for 7 consecutive years, with $12.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents rose 123.56% year-over-year to $12.0 million in Q2 2026; TTM through Jun 2026 was $12.0 million, a 123.56% increase from a year earlier, with the FY2025 full-year figure at $8.9 million, up 17.62% from the prior year.
• Cash & Equivalents was $12.0 million for Q2 2026 at IceCure Medical, up from $8.1 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $23.7 million in Q4 2022 and troughed at -$25000.0 in Q4 2023.
• A 5-year average of $9.4 million and a median of $8.5 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 100.11% in 2023 and soared 30356.0% in 2024, its largest moves.
• Over 5 years, Cash & Equivalents stood at $23.7 million in 2022, then sank by 100.11% to -$25000.0 in 2023, then soared by 30356.0% to $7.6 million in 2024, then increased by 17.62% to $8.9 million in 2025, then soared by 35.26% to $12.0 million in 2026.
• The last three Cash & Equivalents figures came in at $12.0 million (Q2 2026), $8.1 million (Q1 2026), and $8.9 million (Q4 2025), per Business Quant data.